Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
Forty-three patients with metastatic melanoma were treated with a 5 day (18 patients) and a 3 day (25 patients) schedule of high-dose IL-2 11.7 MIU m2 and IFN-alpha 3 MIU m2 i.v. by bolus administration every 8 h, repeated every 21 days for a total of three courses. The 5 day schedule resulted in a high response rate of 41% (CI 18-67%), but was accompanied by severe cardiotoxicity (41%) and central nervous system toxicity (28%). The 3 day schedule was associated with manageable toxicity, but yielded a moderate response rate of 20% (CI 7-43%).
Kruit
W H
WH
Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek, The Netherlands.
Punt
C J
CJ
Goey
S H
SH
de Mulder
P H
PH
Gratama
J W
JW
Eggermont
A M
AM
Bolhuis
R L
RL
Stoter
G
G
D000328:Adult; D000368:Aged; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects; D007694:Killer Cells, Natural / Q000276:immunology; D008297:Male; D008545:Melanoma / Q000276:immunology / Q000556:secondary* / Q000628:therapy*; D008875:Middle Aged
D016898:Interferon-alpha; D007376:Interleukin-2